The trial found that insulin degludec was noninferior to insulin glargine with respect to incident major cardiovascular events.9 The GRADE study is ongoing and randomized approximately 5000 individuals with type 2 diabetes using metformin to the additional medication regimens (sulfonylurea, dipeptidyl peptidase 4 inhibitor, glucagonlike peptide 1 receptor agonist, and insulin). This evidence concerns the gene DPP4 and type 2 diabetes mellitus.